Green Thumb Industries Inc. (OTC:GTBIF – Free Report) – Equities researchers at Alliance Global Partners reduced their FY2024 earnings per share (EPS) estimates for shares of Green Thumb Industries in a note issued to investors on Wednesday, October 30th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings of $0.33 per share for the year, down from their previous estimate of $0.34. The consensus estimate for Green Thumb Industries’ current full-year earnings is $0.35 per share. Alliance Global Partners also issued estimates for Green Thumb Industries’ FY2025 earnings at $0.22 EPS.
Other analysts have also recently issued reports about the company. Ventum Cap Mkts raised Green Thumb Industries to a “strong-buy” rating in a research report on Tuesday, August 6th. Craig Hallum raised Green Thumb Industries to a “strong-buy” rating in a research report on Monday, September 16th.
Green Thumb Industries Trading Up 3.8 %
Shares of OTC GTBIF opened at $10.68 on Monday. The business’s 50-day moving average is $10.30. Green Thumb Industries has a 1-year low of $8.78 and a 1-year high of $16.33. The stock has a market cap of $2.26 billion, a P/E ratio of 38.14 and a beta of 1.40.
Green Thumb Industries Company Profile
Green Thumb Industries Inc manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles, and RHYTHM brands.
Featured Articles
- Five stocks we like better than Green Thumb Industries
- What Makes a Stock a Good Dividend Stock?
- Intel: Is Now the Time to Be Brave?Â
- What is Put Option Volume?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Stock Splits, Do They Really Impact Investors?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Green Thumb Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Green Thumb Industries and related companies with MarketBeat.com's FREE daily email newsletter.